UK Markets open in 1 hr 17 mins

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.71+0.07 (+1.27%)
At close: 06:18PM BST
Full screen
Previous close5.64
Bid0.00 x 0
Ask0.00 x 0
Day's range5.56 - 5.95
52-week range5.56 - 5.95
Avg. volumeN/A
Market cap512.226M
Beta (5Y monthly)0.99
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

    Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

  • Reuters

    Valneva cuts full-year outlook on lower COVID-19 vaccine sales

    The European Commission in July slashed its order for VLA2001 to just 1.25 million doses from a previously targeted 60 million, pointing to European countries being well supplied with other vaccines and a slowdown in vaccination programmes. In February, Valneva had said it expected 350-500 million euros in COVID-19 vaccine sales. In the six months to June, the shot's sales brought in 3.8 million euros and the firm recognised writedowns of 100.6 million linked to the production inventory it bought to meet the initial purchase agreement with the European Commission, and subsequent halt of production.

  • Motley Fool

    How Pfizer Plans to Unlock Another Mass-Market Vaccine

    As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.